

Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:


The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. - 18 (canceled)

19. (original) A method for the prevention or treatment of Alzheimer's disease in a patient at risk of developing said disease or in the course of developing said disease, comprising administering to said patient an effective amount of a compound having a hypocholesterolemic activity wherein said compound does not penetrate into the body after its oral administration.

20. (original) The method as set forth in claim 19 wherein the compound having a hypocholesterolemic activity and not penetrating into the body is a biliary acid reuptake inhibitor.

21. (currently amended) The method as set forth in claim 20, wherein the biliary acid reuptake inhibitor is a compound of formula (IA):



wherein:

R^1 is methyl, ethyl, propyl or butyl;

R^2 is H, OH, NH_2 , or $NH-(C_1-C_6)alkyl$;

R^3 is a saccharide, disaccharide, trisaccharide or ~~quadrisaccharide~~ tetrasaccharide radical, wherein said radicals are optionally mono- or polysubstituted with a sugar protective group;

R^4 is methyl, ethyl, propyl or butyl;

R^5 is methyl, ethyl, propyl or butyl;


Z is $-(C=O)_n-(C_0-C_{16})-alkyl$; $-(C=O)_n-(C_0-C_{16})-alkyl-NH$; $-(C=O)_n-(C_0-C_{16})-alkyl-O$; $-(C=O)_n-(C_0-C_{16})-alkyl-(C=O)_m-$; or a covalent bond;

n is 0 or 1;

m is 0 or 1;

or a pharmaceutically acceptable addition salt thereof, ~~or a physiologically functional derivative thereof.~~

22. (currently amended) The method as set forth in claim 21 wherein the compound is having the following formula:



23. - 24. (canceled)

25. (original) The method as set forth in claim 19 wherein the compound is administered orally.

26. (original) The method as set forth in claim 25 wherein the compound is administered in an amount from about 0.02mg to about 50 mg.
27. (currently amended) The method as set forth in claim 20 wherein one or more biliary acid reuptake inhibitors are administered in combination with one or more compounds chosen from 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) ~~HMG-CoA~~ reductase inhibitors, cholesterol uptake inhibitors, cholesterol synthesis inhibitors or γ and β amyloid- β precursor protein (APP) ~~APP~~ secretase inhibitors.
28. (currently amended) The method composition ~~composition~~ as set forth in claim 27 wherein the various active ingredients are administered simultaneously, separately or spaced out over time.